Ophthalmology Clinical Research is an Ever-Growing Segment in Drug Development.
COSTA MESA, Calif./PRWeb/–WCCT Global, a contract research organization announced they have implemented a strong focus on early and late phase Ophthalmology clinical research. This new capability stems from WCCT Global being a leader in both early and late stage drug development for ocular hypertension and glaucoma for several years. WCCT Global has now established an ophthalmology center of excellence which includes more than 12 leading Ophthalmology Investigator Sites. These highly skilled and experienced Investigators/Clinicians are available to collaborate with sponsors to offer strategies to more rapidly demonstrate local and systemic tolerance, proof of concept and ultimately, safety and efficacy for many ophthalmologic indications. Therefore, WCCT Global can now work with sponsors to design and execute clinical studies to meet the needs of the ophthalmologic product innovator or developer from first-in-man through Phase IV. Dr. Mel Affrime, Sr. VP, Translational Medicine at WCCT Global said, “We have been steadily building this unique capability over the past five years and it gives us great satisfaction to be able to participate in the development of cutting edge treatments that may slow or even reverse the visual impairment that is caused by many eye disorders.”.
Another key aspect to this announcement is WCCT Global has established a nation-wide patient network of diverse ethnicity backgrounds which is necessary to launch a Global Development Program months ahead of the classic separate geographic development paradigms. This strategy provides the sponsor organization, a significant strategic advantage over the competition. In addition to the network, WCCT Global is located in a densely populated and ethnically diverse location which enables a wide variety of subjects available for local study participation.